They suggested that the inhibition of NRF2/ABCB1 signaling (where ABCB1 is a regulatory gene for P-gp) can be considered as a novel strategy to improve the efficacy of chemotherapeutics against colorectal cancer. The gene discussed is NFE2L2; the disease is colorectal cancer.